Skip to content

How to get more dermal filler patients: a plan for injector practices

A front desk team member at a med spa and aesthetic clinic handles a new patient call

This guide is for med spas, dermatology and plastic surgery practices and their front desks: how to advertise lip and facial fillers within what FDA has approved, how to answer first-call questions without giving medical advice, and how to follow up and measure filler requests.

  1. SearchAn adult looks for care near them.
  2. Your pageWhat you treat, who sees them, one way to book.
  3. Call or formThey call or send a request.
  4. Front deskBooks the visit and never guesses a cause.
  5. Clinical teamThe clinician decides the plan.
How a new patient request reaches your practice.

FDA’s dermal fillers page says dermal fillers are medical device implants approved for use in adults 22 years of age or older for specific uses. Among them:

  • Absorbable (temporary) fillers for moderate to severe facial wrinkles and skin folds, such as nasolabial folds and perioral lines.
  • Augmentation of lips, cheeks, chin and the back of the hand.
  • Non-absorbable (permanent) fillers only for nasolabial folds and cheek acne scars.
  • Correction of contour deficiencies, such as wrinkles and acne scars.

The same page lists uses FDA has not approved and recommends against, including body contouring (breasts, buttocks, feet) and injection into the glabella, nose, periorbital area, forehead or neck. It also says needle-free devices are not approved for injecting dermal fillers and that no filler is approved for over-the-counter use. Check each product’s own labeling too: FDA keeps a list of FDA-approved dermal fillers, and FDA notes it reviewed different products for use in specific areas. The general page has not kept up with every approval: FDA’s Premarket Approval database shows several fillers later approved for the infraorbital (under-eye) hollow, for example Juvederm Volbella XC in 2021 and Restylane Eyelight in 2023, even though the general page lists the periorbital area among uses it has not approved. What counts is the approval and labeling of the product you use.

For marketing, that means: advertise an area only if the product you use is approved for it, do not target anyone under 22, name the product type you use, and describe results as dependent on the person. FDA says results depend on the underlying tissue structure and the volume and type of filler, and that how long the effect lasts depends on the filler and the area. The FTC’s Health Products Compliance Guidance says health-related claims must be truthful, not misleading and supported by competent and reliable scientific evidence.

2. Treat it as a medical procedure in every message

FDA advises patients that having filler injected should be considered a medical procedure, not a cosmetic treatment, to look for a licensed health care provider who is trained in the procedure, and to ask about their training and experience. It also warns against buying filler online, because it could be counterfeit or not approved for use in the U.S., and urges providers to inspect packages for authenticity. So:

  • Give the front desk an accurate answer to “Who will inject me, and what training do they have?” Who may inject, and under what supervision, depends on state law; check it with counsel and your licensing boards.
  • Buy product through the manufacturer or authorized distributors, and be ready to say what product is used.
  • Avoid wording like “lunchtime beauty treatment” that presents filler as a non-medical service.

3. Be honest about risks and permanence

FDA says any dermal filler can cause temporary side effects, permanent side effects or both, and that the most concerning risk is unintentional injection into a blood vessel, saying the chances are low but the complications can be serious and may be permanent. It also says it may be difficult or impossible to remove some filler material, especially “permanent” fillers or fillers not made of materials such as hyaluronic acid. Do not use words like “no risk”, “no downtime guaranteed” or “easily reversible” in ads or on calls; leave the risk conversation to the provider at the consultation, using the product’s patient labeling.

4. Answer first-call questions without giving medical advice

  • “How much is it?” Explain how you price (per syringe of a named product, or per area) and that the total is set after assessment.
  • “How long does it last?” FDA says it depends on the filler and the area; use only wording your medical director approves.
  • “Can you do my nose / forehead / under my eyes?” Do not promise; say the provider decides at the consultation. Check whether the product you use is approved for that area; FDA’s general page lists some of these areas as not approved, while specific products have later approvals.
  • “Can I combine it with Botox?” Say the provider will discuss it. FDA notes that combination with neuromodulators has not been evaluated in a controlled clinical study.
  • Ask callers to tell the provider about allergies, bleeding disorders, active skin infections or inflammation, pregnancy or breastfeeding, which FDA lists as things to raise before the procedure.

Our new patient phone script has a call structure you can adapt.

5. Photos, follow-up and tracking

  • Publish before-and-after photos only with written authorization and comparable conditions; see before-and-after photos.
  • Answer new requests quickly; our guide on speed to lead explains why.
  • Text only with the right consent; see texting patients and the TCPA.
  • Track filler requests, consultations and treatments by source, and count repeat visits separately; FDA notes some fillers are absorbed over time and patients may need to repeat the procedure. See tracking new patient sources.

Where MediLeadGen fits

MediLeadGen sends practices requests from people interested in cash-pay elective treatments such as injectables. Each request goes to one practice only, with the person’s consent naming that practice, at a fixed price per delivered request.

See how it works for practices

Questions practices ask

How do we get more dermal filler patients?

Advertise only uses FDA has approved, answer requests quickly, give an accurate answer about who injects and their training, explain pricing as a total after assessment, be honest about risks, follow up with consent, and track filler requests and repeat visits separately.

Can we advertise filler for the nose or under the eyes?

Only for an area the product you use is approved for. FDA’s general dermal fillers page lists the glabella, nose, periorbital area, forehead and neck among uses it has not approved, but FDA has since approved specific fillers for the infraorbital (under-eye) hollow, such as Restylane Eyelight. Check the product’s approval and labeling, and your medical director and counsel, before advertising any area.

What age limit applies to dermal fillers?

FDA says dermal fillers are approved for adults 22 years of age or older, and that safety is unknown in patients under 22. Do not target younger people in ads.

Can we call fillers reversible?

Avoid it. FDA says it may be difficult or impossible to remove some filler material, especially permanent fillers or fillers not made of materials such as hyaluronic acid.

General information for practice teams, not legal or clinical advice. Check product labeling, state scope-of-practice and supervision rules, and your advertising with counsel and your medical director. Last reviewed October 2026.

More resources

All resources for practices